STARLIX
LOE ApproachingNDAORALTABLET
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STARLIX is an oral small-molecule tablet approved by the FDA in December 2000 for an unknown indication, sponsored by Novartis. The mechanism of action and specific therapeutic area remain unspecified in available data. This product represents a mature asset in the Novartis portfolio with approaching loss of exclusivity.
LOE Approaching
With moderate competitive pressure (30%) and approaching loss of exclusivity, the brand team is likely focused on managed decline and lifecycle extension strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching loss of exclusivity, career opportunities on STARLIX are limited and focused on legacy brand management and transition planning. Professionals considering this product should expect a defensive commercial strategy with limited growth potential rather than expansion roles.
Brand ManagerField Sales Representative
Worked on STARLIX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.